Coronary disease & ACS

Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization

CirculationPublished Randomised controlled trial

Primary resultResult — go to the resultHazard ratio 1.007 95% CI 0.78–1.30

Authors' conclusion

The present study in elderly patients with acute coronary syndromes showed no difference in the primary end point between reduced-dose prasugrel and standard-dose clopidogrel.

Study context

Population
Patients >74 years with ACS undergoing PCI40% women
Participants
1,443 patients
Comparison
Prasugrel 5 mg vs clopidogrel 75 mg
Primary endpoint
Composite of:
  • Mortality
  • MI
  • Disabling stroke
  • Rehospitalization for CV causes or bleeding
Follow-up
1 year
Methodological detailsmulticentre, open-label, blinded end point, superiority, planned interim analysis, Enrollment interrupted, per prespecified criteria, after a planned interim analysis because of futility for efficacy
  • Multicentre
  • Open-label
  • Blinded end point
  • Superiority
  • Planned interim analysis
  • Enrollment interrupted, per prespecified criteria, after a planned interim analysis because of futility for efficacy

Primary result

As reported in the abstract

Hazard ratio

1.007

95% CI 0.78–1.30

P = 0.955

Events by treatment group

Prasugrelvs Clopidogrel
HR 1.007 (95% CI 0.78–1.30); P = 0.955

Further findings

OutcomePrasugrelClopidogrelOR (95% CI)P value
Definite/probable stent thrombosis0.7%1.9%0.36 (0.13–1.00)P = 0.06

Safety

OutcomePrasugrelClopidogrelOR (95% CI)P value
BARC type ≥2 bleeding4.1%2.7%1.52 (0.85–3.16)P = 0.18

Original publication

Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation. Published 19 February 2018. doi:10.1161/circulationaha.117.032180

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.